Physician profile
Charmille A Hare
NPI 1114140704
$2,090.20
in general payments reported to CMS, 2019-2025
24 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $261 · 2021: $99.56 · 2022: $252 · 2023: $359 · 2024: $489 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $248.49 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $242.56 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $207.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $186.02 | 2019-2022 | |
| Pfizer INC. | $116.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.59 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $108.97 | 2019-2022 | |
| Amgen INC. | $91.26 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $75.90 | 2022-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $56.89 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $50.57 | 2019-2020 | |
| Corcept Therapeutics | $48.44 | 2025 | Korlym |
| Ibsa Pharma INC. | $43.44 | 2022-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $28.29 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $28.01 | 2022-2024 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.27 | 2025 | Voquezna |
| Halozyme INC | $18.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.07 | 2020 | |
| Horizon Therapeutics Plc | $14.52 | 2019 | |
| Phadia US INC. | $14.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmille Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.